Legend Biotech Launches ELITE Program for Cell Therapy Innovators
Legend Biotech Corporation announced the launch of its inaugural Emerging Leadership & Innovation in Cell Therapy Excellence (ELITE) Program. This annual grant initiative aims to recognize and support early-career healthcare professionals who are advancing novel cell therapy approaches for the treatment of multiple myeloma. The program is guided by an independent steering committee of experts and will award grants in two categories: Emerging Educator and Emerging Innovator. Applications are open until November 20, 2026.
Key Highlights
- Legend Biotech launches inaugural Emerging Leadership & Innovation in Cell Therapy Excellence (ELITE) Program.
- Annual grant initiative to support early-career healthcare professionals in multiple myeloma cell therapy research.
- Applications open through November 20, 2026, with recipients notified in December 2026.
- Program guided by an independent steering committee of experts in cellular therapy.
- Grants awarded in two categories: Emerging Educator and Emerging Innovator.
Price Impact
More from LEGN
Legend Biotech Holds 2026 AGM; Approves Auditor, Director Elections, and Share Plan Amendment
Legend Biotech Q2 Net Income $33.2M; CARVYKTI Sales +50% to $657M
Legend Biotech CEO Ying Huang Steps Down; Alan Bash Appointed Interim CEO